Tristel PLC
LSE:TSTL
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
350
500
|
Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Tristel PLC
Income from Continuing Operations
Tristel PLC
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Tristel PLC
LSE:TSTL
|
Income from Continuing Operations
ÂŁ6m
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
18%
|
||
Abingdon Health PLC
LSE:ABDX
|
Income from Continuing Operations
-ÂŁ3.5m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
ConvaTec Group PLC
LSE:CTEC
|
Income from Continuing Operations
$130.3m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
||
Inspecs Group PLC
LSE:SPEC
|
Income from Continuing Operations
-ÂŁ997k
|
CAGR 3-Years
52%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Advanced Medical Solutions Group PLC
LSE:AMS
|
Income from Continuing Operations
ÂŁ11.1m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-1%
|
||
Cambridge Nutritional Sciences PLC
LSE:CNSL
|
Income from Continuing Operations
-ÂŁ328k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Tristel PLC
Glance View
Tristel Plc engages in the design, development, manufacture, and sale of infection control, contamination control and hygiene products. The company is headquartered in Snailwell, Cambridgeshire and currently employs 189 full-time employees. The company went IPO on 2005-06-01. The Company’s technology is a chlorine dioxide formulation used by hospitals for the high-level disinfection of medical devices and the sporicidal disinfection of environmental surfaces. The Company’s segments include Hospital medical device decontamination and Hospital environmental surface disinfection. The firm manufactures and sells medical device decontamination products that are used primarily for infection control in hospitals. The firm also manufactures and sells hospital environmental surface disinfection products. The Tristel brand offers airway management, cardiology, ear, nose and throat, ophthalmology, endoscopy, phlebotomy, surfaces, ultrasound, urology, and women's health. The Crystel brand offers pharmaceutical, cosmetic and toiletry (PCT), cleanroom disinfectants and laboratory disinfectants. The company markets its products under the Tristel, Anistel, and Crystel brands.
See Also
What is Tristel PLC's Income from Continuing Operations?
Income from Continuing Operations
6m
GBP
Based on the financial report for Dec 31, 2023, Tristel PLC's Income from Continuing Operations amounts to 6m GBP.
What is Tristel PLC's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
18%
Over the last year, the Income from Continuing Operations growth was 74%. The average annual Income from Continuing Operations growth rates for Tristel PLC have been 10% over the past three years , 12% over the past five years , and 18% over the past ten years .